Sugi Predict

Sugi Predict / Compounds / SCHEMBL287699

SCHEMBL287699

SCHEMBL287699

O=C(O)c1ncccc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.57
▸ ATM Q13315 1/20 0.57
▸ MAPT P10636 2/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ AGER Q15109 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ CYP1A2 P05177 1/20 0.50
▸ CHRNB2 P17787 1/20 0.46
▸ CHRNB4 P30926 1/20 0.46
▸ CHRNA3 P32297 1/20 0.46
▸ CHRNA4 P43681 1/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.46
▸ MKNK2 Q9HBH9 1/20 0.46
▸ MYC P01106 1/20 0.46
▸ NAPRT Q6XQN6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467068 0.92 KDM4E (0.54) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL28279600 0.89 KDM4E (0.53) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL11298868 0.88 KDM4E (0.49) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL27654772 0.88 KDM4E (0.49) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL2323790 0.85 KDM4E (0.50) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL5258713 0.85 KDM4E (0.50) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL231896 0.85 MKNK1 (0.56) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL29601706 0.85 KDM4E (0.46) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL6902624 0.85 KDM4E (0.46) KDM4EATMMAPTL3MBTL1ALDH1A1
SCHEMBL17878183 0.85 KDM4E (0.46) KDM4EATMMAPTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113880063-B Aluminum removal method for phosphorus iron slag after lithium extraction of waste lithium iron phosphate and preparation method for battery grade iron phosphate 广东光华科技股份有限公司 2023-05-02 — — CN claimed
CN-113880063-A Aluminum removing method for ferrophosphorus slag after lithium extraction of waste lithium iron phosphate and preparation method of battery-grade ferric phosphate 广东光华科技股份有限公司 2022-01-04 — — CN claimed
CN-110759926-B Water-soluble phenylpyridine derivative-cucurbituril supramolecular pseudorotaxane assembly and application thereof in cell phosphorescence imaging 南开大学 2021-11-12 — — CN claimed
CN-110759926-A Water-soluble phenylpyridine derivative-cucurbituril supramolecular pseudorotaxane assembly and application thereof in cell phosphorescence imaging 南开大学 2020-02-07 — — CN claimed
CN-106654032-A Monolayer full-phosphorescence white-light organic electroluminescent device and preparation method thereof 苏州大学 2017-05-10 — — CN claimed
CN-103987711-B 8-carbamoyl-2- (2, 3-disubstituted pyridin-6-yl) -1,2,3, 4-tetrahydroisoquinoline derivatives as apoptosis inducers for the treatment of cancer and immune and autoimmune diseases 艾伯维公司 2016-08-24 — — CN claimed
EP-2511268-B1 OXAZINE DERIVATIVE SHIONOGI & CO (JP) 2016-07-13 — — EP claimed
CN-102482268-B 2-Aminodihydro [1,3] thiazines as BACE2 inhibitors for the treatment of diabetes HOFFMANN LA ROCHE 2014-11-26 — — CN claimed
EP-2509966-B1 AMINO OXAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-10-22 — — EP claimed
CN-103987711-A 8-carbamoyl-2- (2, 3-disubstituted pyridin-6-yl) -1,2,3, 4-tetrahydroisoquinoline derivatives as apoptosis inducers for the treatment of cancer and immune and autoimmune diseases ABBVIE INC 2014-08-13 — — CN claimed
US-8461160-B2 Dihydropyrimidinones HOFFMANN-LA ROCHE, INC. (US) 2013-06-11 — — US claimed
US-20130096107-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES HOFFMANN-LA ROCHE INC. (US) 2013-04-18 — — US claimed
EP-2509966-A1 AMINO OXAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-17 — — EP claimed
CN-102652129-A Amino oxazine derivatives HOFFMANN LA ROCHE 2012-08-29 — — CN claimed
EP-2475658-A1 2 -AMINODIHYDRO [1, 3]THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-07-18 — — EP claimed
CN-102482268-A 2-Aminodihydro [1,3] thiazines as BACE2 inhibitors for the treatment of diabetes HOFFMANN LA ROCHE 2012-05-30 — — CN claimed
CN-102421760-A Dihydropyrimidinones useful as BACE2 inhibitors HOFFMANN LA ROCHE 2012-04-18 — — CN claimed
US-20110065695-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES HOFFMANN-LA ROCHE, INC. 2011-03-17 — — US claimed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 — — WO claimed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096107-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES SLC5A2, SLC5A1, GLP1R KDM4E 1845/4885ATM 2475/4885MAPT 3406/4885
US-20110065695-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES SLC5A2, SLC5A1, GLP1R KDM4E 1845/4885ATM 2475/4885MAPT 3406/4885
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 KDM4E 2548/4885ATM 4640/4885MAPT 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.